At the one-year anniversary of the first detection in China of the SARS-CoV-2 virus, the pathogen that causes Covid-19, there are now two highly effective vaccine candidates developed at a record pace. | Spencer Platt/Getty Images
The companies say their vaccine could begin distribution to high-risk people by mid-December.
Just last week, Pfizer and BioNTech revealed that their experimental Covid-19 vaccine, called BNT162b2, was at least 90 percent effective in an early analysis. On Wednesday, the pharmaceutical and biotech companies reported that their vaccine was even more effective after it cleared more clinical trial benchmarks for safety and efficacy. And on Friday, they said they are requesting an emergency use authorization (EUA) from the Food and Drug Administration.
If granted an EUA, the BNT162b2 vaccine could be administered to certain high-risk groups in the United States — most likely health workers
Upstate News Headlines
- Weekend Things to Do: Greenville South Carolina
- Inaugural poet Amanda Gorman: 'Even as we grieved, we grew.'
- Vice President Harris: A new chapter opens in US politics
- LIVE: Biden sworn in as America's 46th president, Harris becomes first female VP
- Carolina prisons get first wave of COVID-19 vaccine doses
- US Surgeon General Jerome Adams asked to step down by Biden team
- ‘Tiger King’ Star Joe Exotic Expected Pardon From President Trump, Books Limo
- SCEL: No Tuesday winner, Mega Millions jackpot now up to $970 million
- The Latest: Biden calls on Americans to overcome divisions
- Read the letters outgoing presidents left for their successors in the Oval Office
- Colts quarterback Philip Rivers retires from NFL after 17 seasons